March 24, 2026

No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma

Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response af...

The ASCO Post

March 01, 2026

Video: 3-Year Data Show Vision Gains With Optogenetic Therapy for RP

Positive outcomes from Nanoscope's MCO-010 trial for retinitis pigmentosa highlight a potential breakthrough in vision restoration, as showcased by Dr. Christine Nichols Kay at the 2026 Macula Society meeting.

Retinal Physician

February 26, 2026

Why Riva Still Matters

Fernando Lancas reflects on the meeting that shaped modern chromatography – and why its return matters now more than ever

The Analytical Scientist

February 24, 2026

Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer

“Encorafenib/cetuximab plus FOLFIRI is an additional standard of care for patients needing FOLFIRI in the first-line setting,” reported study authors at the 2026 ASCO Gastrointestinal Cancers Symposiu...

The ASCO Post

February 09, 2026

Managing Idiopathic Acute Pancreatitis

Expert panel weighs evidence for genetic testing, cholecystectomy, and ERCP in patients with unexplained acute pancreatitis amid limited guideline direction.

Conexiant

January 08, 2026

Digital Technology Is Ready. Are We?

Leaders at Digital Pathology and AI Europe 2025 unpack hesitation, regulation, and the path to real-world deployment

The Pathologist

November 21, 2025

Positive trends in chronic HCV mortality 

“DAAs have revolutionized the management of HCV by making it a curable disease.”

Conexiant

November 21, 2025

Tirzepatide tops semaglutide for cardiometabolic protection in MASLD

The study authors recommend prospective head-to-head trials to validate the findings.

Conexiant

November 21, 2025

ALD-related HCC mortality surges 

 The findings underscore the urgent need for targeted prevention strategies among high-risk group.

Conexiant

November 20, 2025

New score challenges old predictors

"MERAGE has superior performance for predicting return to drinking (RTD) compared to HRAR in AH."

Conexiant